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Global Annual Death from tobacco-related illness, 2003 
Canada 
45,000 
USA 
440,000 
South America 
221,000 
Africa 
158,000 
Russia 
330,000 
China 
800,000 
South-East 
Asia 
1,035,000 
Australia 
18,700 
Taiwan 
19,000 
Wen, Ching Pan (2003). The Taiwan Tobacco Atlas, United medical Foundation, National Health Research Institutes 
Estimated tobacco-related deaths: 
2005: 5.4 million              2015: 6.4 million             2030: 8.3 million 
 
 
Mathers CD, Loncar D (2006) Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med 3(11): e442. doi:10.1371/journal.pmed.0030442 
Prevalence of Current Smoking in Canada (age 15+) 
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Health Canada. Canadian Tobacco Use Monitoring Survey 
2009, Summary of Annual Results. 
Total: 18.0%  
Male: 19.2% 
Female: 15.9% 
What’s in a Cigarette? 
 
Smoking cigarettes with lower tar and nicotine provides no health benefit.2 
Acetone 
Butane 
Arsenic 
Cadmium 
Carbon monoxide 
Toluene 
Paint stripper 
Lighter fluid 
Ant poison 
Car batteries 
Car exhaust fumes 
Industrial solvent 
Chemicals in 
Tobacco Smoke1 Also Found In… 
1. World Health Organization. Tobacco: deadly in any form or disguise, 2006.  
2. Health Canada. What’s in Cigarette smoke?, August 2005. 
Tobacco smoke: ≥ 4000 chemicals1, ≥ 50 carcinogenic2 
 Smoking-Attributable Causes of Death 
 
#1 Lung cancer  
#2 Ischemic heart disease 
#3 Chronic airways  
obstruction1 Cancers1  Lung,  
Bronchus Lip, Oral cavity/pharynx 
Esophagus Larynx, trachea 
Cervix uteri Urinary bladder 
Stomach2 Colon2  
Leukemia2 Pancreas 
Kidney,  Liver2 
  other urinary 
Cardiovascular disease1 
Ischemic heart disease 
Cerebrovascular disease 
Rheumatic heart disease 
Atherosclerosis 
Hypertension  
Aortic aneurysm 
Pulmonary heart disease 
Other arterial disease 
 
Respiratory disease1 
Chronic airways obstruction 
Asthma 
Bronchitis/emphysema 
Pneumonia/influenza 
Respiratory tuberculosis 
Paediatric disease1 
Low birth weight 
Respiratory conditions-newborn 
Respiratory distress syndrome 
Sudden Infant Death Syndrome 
Reproductive Problems2  
Reduced fertility 
Spontaneous Abortion 
Placental abruption 
1.  Makomaski Illing EM, Kaiserman, MJ. Can J Public Health 2004;95:38-44. 
2.  Ghadirian, P (for Health Canada). Sleeping with a Killer: The Effects of Smoking on Human Health. Health Canada. Sept. 2002. 
Prevalence  
Nearly 70%-90% of individuals in drug treatment programs concurrently 
use tobacco (Best et al, 1998; Clark et al, 2001) 
 Kalman, Morissette and George (2005), Am. J. Addict., 14: 106-123  
• “these patients don’t want to quit” 
 
• “these patients will relapse if they try to quit” 
 
• “these patients have more important issues in their lives 
     ….they should just be allowed to smoke…”  
 
• “these patients are unable to quit” 
 
 
 
Arguments for Not Providing Tobacco 
Treatment…. 
 
Patients Receiving Substance Use and 
Psychiatric Treatment Want To Quit….. 
•Most smokers (80%) in a MMT population were “somewhat” or 
“very” interested in quitting. 
 
 
•In an outpatient program for “alcohol abusers”, more than 75% 
 were willing to consider stopping smoking. 
 
•In a review of 9 studies assessing motivation to quit smoking, 
more than 50% of all smokers with a psychiatric disorder are 
contemplating to quit smoking in the next 6months or 30days. 
 
 
 Richter KP et al.(2001) Tobacco Use and Quit Attempts Amongst Methadone Clients. AJPH 
Ellingstad TP et al (1999) Alcohol Abusers Who Want To Quit Smoking. Drug and Alcohol Dependence. 
Siru, R., Hulse, G. K., & Tait, R. J. (2009). Assessing motivation to quit smoking in people with mental illness: a review. 
Addiction, 104(5), 719-733  
Smoking Cessation Does Not Impair 
Addiction Treatment But may affect 
Psychiatric illness …. 
• Smoking cessation efforts delivered during addictions treatment 
appeared to ENHANCE rather than compromise long term sobriety.  
 
•However, smoking cessation is associated with increased risk of 
depressive episodes among individuals with Major Depression 
 
•May result in adverse drug reaction due to increased available 
serum levels of antipsychotics (previously lowered by smoking) 
Prochaska JJ et al (2004).A meta-analysis of smoking cessation interventions with individuals in substance abuse 
treatment or recovery. Journal Consult Clin. Psychol.  
Glassman, A. H., Covey, L. S., Stetner, F., & Rivelli, S. (2001). Smoking cessation and the course of major depression: a 
follow-up study. The Lancet, 357(9272), 1929-1932  
Zullino, D. F., Delessert, D., Eap, C. B., Preisig, M., & Baumann, P. (2002). Tobacco and cannabis smoking cessation can 
lead to intoxication with clozapine or olanzapine. International Clinical Psychopharmacology, 17(3), 141-143  
These Patients CAN Quit But… 
• Earlier meta-analysis (n = 19 studies) addressing smoking 
cessation among individuals in addiction treatment and 
recovery found: 
– Increased cessation at end of 12 weeks treatment (BUT NO 
SIGNIFICANT EFFECT AT 6 MONTHS!) 
 
 
• Recent study found end-of-treatment smoking cessation rates 
of 24% vs 19% for individuals with schizophrenia vs. those 
without psychosis (but with another psychiatric disorder) 
–  Longer duration of treatment a significant predictor of successful 
cessation.                      
      
   
Prochaska JJ et al (2004).A meta-analysis of smoking cessation interventions with individuals in substance abuse 
treatment or recovery. Journal Consult Clin. Psychol  
Selby et al. (2010). Individualized smoking cessation treatment in an outpatient setting: Predictors of outcome in a 
sample with psychiatric and addictions co-morbidity. Addictive Behaviors, 35(9):811-7 
 
 
 TDC Program Description  
 
 
Quitting smoking is a process and not  
an event 
Program Description 
• The Tobacco Dependence Clinic (TDC) is a program that 
provides behavioural counselling and up to 26 weeks of no-
cost pharmacotherapy for clients through VCH Mental Health 
& Addiction Services 
 
• Program is run with a team of nurses, counsellors, respiratory 
therapists, and a physician 
 
• Currently in 7 locations:   
– Pacific Spirit Community Health Centre 
– Raven Song Community Health Centre 
– Three Bridges Community Health Centre 
– Downtown Community Health Centre  
– Pender Community Health Centre  
– Centre for Concurrent Disorders  
– Rainier Hotel 
Intake 
Eligibility: 
• 19 years or older 
• Tobacco dependent 
• Have a history of substance use disorder (SUD) and/or psychiatric disorder 
(PD) 
• Financially disadvantaged 
 
Assessment: 
• 1 hour evaluation of medical, psychiatric, substance and tobacco use 
history 
• Expired air CO is determined and a treatment plan is developed in 
consultation with client 
Phases of Treatment  
 
8 
W
ee
ks
 
U
p 
to
 2
6 
W
ee
ks
 
Tailored 
 Pharmacotherapy 
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Behavioral Counseling  
 
Support Group 
Behavioural Counseling (Weeks 1-8) 
• Phase 1: engagement in the process – weeks 1-2 
 
• Phase 2: planning for change – weeks 3-4 
 
• Phase 3: sustaining change – weeks 5-8 
Combination Pharmacotherapy 
Nicotine Replacement Therapy 
 
 
 
Oral Medications  
 
 
 
Patch 
Gum 
Lozenge 
Inhaler 
Zyban 
Champix 
Smoking Cessation  
Outcome Evaluation 
TDC Clinics 
Pacific Spirit, Sept, 2007 Three Bridges, March, 2008 
Downtown Community 
 Health Centre, Sept, 2008 Raven Song, Sept, 2010 
TDC sites contd 
Pender Clinic, Sept, 2010 
Centre for Concurrent Disorders,  
Feb, 2011 
Ranier Hotel, March, 2011 
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Substance Use Disorder & Psychiatric Disorder History 
(N = 739) 
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None Anxiety 
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Co-occurring Disorders history  
(either past or current, N = 739) 
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None (n = 25) 
Psychiatric only (n = 57) 
Substance Use only (n = 146) 
Both (n = 511) 
3.4% 
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Percent % 
Sample Characteristics (N = 739) 
Mean Stand. Dev. 
Age of participant (years) 
 
47.2 11.4 
Age at smoking initiation (years) 
 
14.9 5.2 
Importance of quitting (scale of 0 ‘low’ to 10 ‘high’) 9.0 1.3 
Confidence in quitting (scale of 0 ‘low’ to 10 ‘high’) 
 
7.3 2.3 
Number of cigarettes smoked per day 
 
20.6 10.8 
Fagerstrom Test for Nicotine Dependence  
(scale of 0 ‘low’ to 10 ‘high’) 
 
6.0 2.1 
CO level at baseline (ppm) 20.1 12.4 
Sample for Outcomes Assessment  
739 
Completed intake and orientation 
 
(Sept 2007 to March 2011) 
240 
•Not engaged in the program (i.e., had 
two or less contacts with the program) 
•No gender reported 540 
Intent to treat 
139 
Program non-completers 
406 
program completers 
Smoking cessation: 7-day point-prevalence of abstinence at end of treatment  
(i.e., anytime between 8 weeks to 26 weeks) verified by expired CO levels 
Program Completion (n = 406/540) 
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Smoking Cessation* Outcomes at end-of-treatment  
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Smoking cessation by SUD and PD among 
program completers (n = 406)* 
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* No statistically significant differences between groups 
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Multivariate predictorsa of smoking cessation at end of 
treatment (i.e., within 26 weeks) (n = 373) 
Predictors Odds Ratio 95%CI 
History of Psychiatric Disorder 
None (reference) 
Mood disorder 
Anxiety disorder 
Psychotic disorder 
 
1.0 
.74 
.42* 
.88 
 
- 
.40-1.36 
.19-.93 
.33-2.38 
       CO level at baseline 
.98* .96-1.00 
       Number of Visits to the TDC 
1.10*** 1.06-1.14 
a. Only variables which were significantly predictive of smoking cessation in the final multivariate 
model are shown.  
 
* = p <.05, ** = p <.001, *** = p <.001 
Summary of Key Findings 
• Smoking abstinence at end of program: 
 
– Intent to treat analysis: 31%(167/540)   
– Among program completers: 41%(167/406)  
 
 
• Significant predictors of abstinence: 
– Having a history of an anxiety disorder is predictive of being less 
likely to quit smoking when compared to having no history of a 
psychiatric disorder.   
– Having a lower CO level at program enrolment was a significant 
predictor of being more likely to quit  
– Attending the TDC program for a longer duration was a significant 
predictor of being more likely to quit. 
 
 
Conclusions 
 
• The Tobacco Dependence Clinic provides an innovative 
model of tailored tobacco dependence treatment which 
combines behavioural counselling with no-cost NRT for 
individuals with a history of substance use and/or 
psychiatric disorders. 
 
• With intensive tobacco dependence treatment provided 
within addictions services, individuals with a history of 
substance use and/or psychiatric disorders are able to 
achieve smoking abstinence. 
 
 
 


